Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Agalsidase beta biosimilar - Bio Sidus S.A.

Next Previous
Search
Drug Profile

Agalsidase beta biosimilar - Bio Sidus S.A.

Alternative Names: AGA BETA BS; Recombinant human alpha galactosidase A - Bio Sidus S.A.

Latest Information Update: 10 May 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bio Sidus S.A.
  • Developer Biosidus S.A.
  • Class Galactosidases; Glycoproteins; Isoenzymes; Recombinant proteins
  • Mechanism of Action Alpha-galactosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Fabry's disease

Most Recent Events

  • 13 Dec 2022 Phase-III clinical trials in Fabry's disease in Argentina (Parenteral) (NCT05843916)
  • 17 Apr 2022 Bio Sidus S.A. completes a phase I trial in Fabry's disease (In volunteers) in Argentina (IV, infusion) (NCT05343715)
  • 23 Oct 2021 Phase-I clinical trials in Fabry's disease (In volunteers) in Argentina (IV) (NCT05343715)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top